TY - JOUR
T1 - International validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis
T2 - A phase IV study
AU - Halkett, Georgia K.B.
AU - Wigley, Charles Adam
AU - Aoun, Samar M.
AU - Portaluri, Maurizio
AU - Tramacere, Francesco
AU - Livi, Lorenzo
AU - Detti, Beatrice
AU - Arcangeli, Stefano
AU - Lund, Jo Asmund
AU - Kristensen, Are
AU - McFadden, Nathalie
AU - Grun, Arne
AU - Bydder, Sean
AU - Sackerer, Irina
AU - Greimel, Elfriede
AU - Spry, Nigel
N1 - Funding Information:
This project was funded by the EORTC Quality of Life Group. Celine Fournier and Melissa Berg assisted in the management of the project and data collation. Additional collaborators include: Dr. Myriam Bouchard, Dr. Anne-Sophie Lessard and Dr. Julie Villa. Associate Professor Halkett is currently supported by a Research Fellowship from the Cancer Council of WA. Dr. Wigley is funded by the Australian Government’s Collaborative Research Networks (CRN) program. We also thank the participants who participated in the study. Copies of the final module are available, upon compeletion of a signed agreement at the EORTC Quality of Life Department at http://groups.eortc.be/qol
Funding Information:
This project was funded by the EORTC Quality of Life Group. A/Prof Halkett is currently supported by a Cancer Council of WA Research Fellowship.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/8/29
Y1 - 2018/8/29
N2 - Background: Although patients experience radiation proctitis post radiotherapy no internationally tested instruments exist to measure these symptoms. This Phase IV study tested the scale structure, reliability and validity and cross-cultural applicability of the EORTC proctitis module (QLQ-PRT23) in patients who were receiving pelvic radiotherapy. Methods: Patients (n = 358) from six countries completed the EORTC QLQ-C30, QLQ-PRT23 and EORTC Quality of Life Group debriefing questions. Clinicians completed the EORTC Radiation Therapy Oncology Group scale. Questionnaires were completed at four time-points. The module's scale structure was examined and validated using standard psychometric analysis techniques. Results: Three items were dropped from the module (QLQ-PRT23 QLQ-PRT20). Factor analysis identified five factors in the module: bowel control; bloating and gas; emotional function/lifestyle; pain; and leakage. Inter-item correlations were within r = 0.3-0.7. Test-Retest reliability was high. All multi-item scales discriminated between patients showing symptoms and those without symptomology. The module discriminated symptoms from the clinician completed scoring and for age, gender and comorbidities. Conclusion: The EORTC QLQ-PRT20 is designed to be used in addition to the EORTC QLQ-C30 to measure quality of life in patients who receive pelvic radiotherapy. The EORTC QLQ-PRT20 is quick to complete, acceptable to patients, has good content validity and high reliability.
AB - Background: Although patients experience radiation proctitis post radiotherapy no internationally tested instruments exist to measure these symptoms. This Phase IV study tested the scale structure, reliability and validity and cross-cultural applicability of the EORTC proctitis module (QLQ-PRT23) in patients who were receiving pelvic radiotherapy. Methods: Patients (n = 358) from six countries completed the EORTC QLQ-C30, QLQ-PRT23 and EORTC Quality of Life Group debriefing questions. Clinicians completed the EORTC Radiation Therapy Oncology Group scale. Questionnaires were completed at four time-points. The module's scale structure was examined and validated using standard psychometric analysis techniques. Results: Three items were dropped from the module (QLQ-PRT23 QLQ-PRT20). Factor analysis identified five factors in the module: bowel control; bloating and gas; emotional function/lifestyle; pain; and leakage. Inter-item correlations were within r = 0.3-0.7. Test-Retest reliability was high. All multi-item scales discriminated between patients showing symptoms and those without symptomology. The module discriminated symptoms from the clinician completed scoring and for age, gender and comorbidities. Conclusion: The EORTC QLQ-PRT20 is designed to be used in addition to the EORTC QLQ-C30 to measure quality of life in patients who receive pelvic radiotherapy. The EORTC QLQ-PRT20 is quick to complete, acceptable to patients, has good content validity and high reliability.
UR - http://www.scopus.com/inward/record.url?scp=85053024376&partnerID=8YFLogxK
U2 - 10.1186/s13014-018-1107-x
DO - 10.1186/s13014-018-1107-x
M3 - Article
C2 - 30157890
AN - SCOPUS:85053024376
SN - 1748-717X
VL - 13
JO - Radiation Oncology
JF - Radiation Oncology
IS - 1
M1 - 162
ER -